At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives.
As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, nephrology, pulmonology and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines and active pharmaceutical ingredients.
Together, we’re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service.
To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Equal Opportunity Employer
Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Location: United States, New Jersey
Employees: 1001-5000
Founded date: 1867
Investors 3
Date | Name | Website |
17.07.2021 | ARCH Ventu... | archventur... |
- | Sofinnova ... | sofinnova.... |
- | Signet Hea... | signetheal... |
Mentions in press and media 41
Date | Title | Description | Source |
12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030... | Opioid Use Disorder (OUD) Market Opioid Use Disorder Market Analysis, Industry Trends and Growth Out... | einpresswi... |
10.10.2023 | Mallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1... | - | wsj.com/ar... |
12.05.2023 | API Innovation Center to Solidify U.S. Active Pharmaceutical... | API Innovation Center Announced Agreement to Accelerate Adoption of Low-Cost Pharmaceutical Manufact... | einpresswi... |
20.09.2022 | Prevent Blindness Declares Second Annual Inflammatory Eye Di... | Prevent Blindness declares Sept. 26 – Oct. 2, 2022, as the second annual Inflammatory Eye Disease (I... | prweb.com/... |
17.06.2022 | Attorney General Tong Announces $230 Million Settlement with... | Press Releases 06/17/2022 Attorney General Tong Announces $230 Million Settlement with Mallinckrodt ... | einpresswi... |
22.02.2022 | Mallinckrodt chalks up CRL to packaging and labeling facilit... | Mallinckrodt has been handed a complete response letter in connection to its NDA seeking approval fo... | endpts.com... |
12.11.2021 | The National Alliance for Caregiving Releases a New White Pa... | The paper discuses significant components that contribute to systemic setbacks, including specifics ... | prweb.com/... |
28.10.2021 | Mallinckrodt and Terumo Blood and Cell Technologies Announce... | - In a dual-review process, two independent advisory committees to the Australian Minister for Healt... | marketscre... |
21.09.2021 | Prevent Blindness Declares First-ever Inflammatory Eye Disea... | Prevent Blindness has declared Sept. 27 – Oct. 3, 2021, as "Inflammatory Eye Disease Awareness ... | prweb.com/... |
03.09.2021 | Mallinckrodt Reaches Settlements with the Official Committee... | prnewswire... |
Show more